STAAR Surgical

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STAAR Surgical reports robust Q4 performance and eyes U.S. growth

STAAR Surgical's Q4 2022 earnings call highlighted strong performance, growth opportunities in key markets, and strategic investments for future success. Despite challenges in China, the company remains optimistic about market recovery and growth prospects. With a focus on EVO lens adoption and increased investments, STAAR is well-positioned for continued growth and market expansion.

STAAR Surgical excels in Q1 with strong global sales growth

STAAR Surgical's Q1 2023 earnings call highlighted robust global sales growth, positive market reception, and strategic investments for future expansion. The company aims to strengthen its market position through targeted growth strategies and operational enhancements.

STAAR Surgical reports record Q2 sales, eyes global expansion

STAAR Surgical's Q2 2023 performance showcased record sales and growth, driven by the EVO family of ICLs.
The company's strong presence in APAC, particularly China, and confidence in high-growth outlook are notable.
Challenges include market declines and pricing dynamics, but opportunities lie in global expansion and strategic initiatives.
Balancing growth and profitability remains a focus, with ongoing efforts to enhance market presence and address challenges.

STAAR Surgical reports resilient Q3 performance amidst market challenges

STAAR Surgical's Q3 2023 performance reflects continued growth in ICL sales despite challenges.
The company is navigating macroeconomic headwinds while focusing on market-building initiatives.
Despite a decline in operating income, STAAR remains confident in its growth prospects.
STAAR's strategic focus on new products and market expansion positions it for future success.

STAAR Surgical posts robust Q4 results, eyes global expansion opportunities

STAAR Surgical's strong financial performance and strategic initiatives position the company for continued growth and market leadership.
Challenges from market competition and macroeconomic factors require careful navigation, but opportunities in expanding markets and operational enhancements offer avenues for growth.
With a focus on innovation, profitability, and global expansion, STAAR is poised to capitalize on market trends and drive sustainable growth in the coming years.

STAAR Surgical surpasses Q1 sales targets, eyes global expansion

STAAR Surgical's Q1 2024 performance exceeded expectations, driven by strong global sales growth and strategic milestones. Challenges include addressing discrepancies in sales and unit growth. The company is poised to capitalize on opportunities in China, surgeon training, and international expansion.

STAAR Surgical posts robust Q2 results, eyes global expansion

STAAR Surgical's Q2 2024 performance reflects strong sales growth, improved profitability, and a positive outlook for fiscal 2024.
The company's strategic strengths in global market expansion and innovation position it well for future growth and achieving long-term sales targets.
Challenges in managing operating expenses and sustaining growth rates in key markets require continued strategic focus and operational efficiency.
Opportunities in expanding market presence, driving innovation, and leveraging financial strength present avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

The consensus price target hints at a 75.9% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Staar Surgical (STAA) Could Surge 76%: Read This Before Placing a Bet

Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates

STAAR Surgical Company (NASDAQ:STAA ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Brian Moore - Vice President, Investor, Media Relations and Corporate Development Caren Mason - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Bill Plovanic - Canaccord Zach Weiner - Jefferies Ryan Zimmerman - BTIG Chris Cooley - Stephens Andrew Brackmann - William Blair David Saxon - Needham Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear.

STAAR Surgical Company's (STAA) CEO Caren Mason on Q1 2022 Results - Earnings Call Transcript

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended April 1, 2022. First Quarter 2022 Overview Record Net Sales of $63.2 Million Up 25% from the Prior Year Quarter ICL Sales of $58.7 Million Up 26% from the Prior Year Quarter Record ICL Units Up 29% from the Prior Year Quarter Gross Margin at 77.9%

STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y

The stock price isn't tightly connected to its fundamentals.

After Falling More Than 56% in a Year, Is STAAR Surgical Doomed?

Concerns about a potential drop in consumer spending may have hurt the stock.

Why STAAR Surgical Stock Dropped 12% This Week

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progre

STAAR Surgical to Report First Quarter Results on May 4, 2022

STAAR has a 20% 5-year average of year over year revenue growth and high gross margins of 77.5% for 2021 and 72.4% for 2020.

Is STAAR Surgical A Watchlist Contender?

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first implants of the EVO Visian® Implantable Collamer® lens (EVO ICL) in the U.S. The Company also announced today its program of meetings and presentations during the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Washington, D.C., April 22 through April 2

STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S.

The company should have brighter days ahead with the FDA approval of the EVO implantable lens.

STAAR Surgical Surged Today: Is the Stock a Buy Now?

The FDA approved STAAR Surgical Company's (NASDAQ: STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction.

Why STAAR Surgical's Shares Are Gaining Today

The FDA approved the company's EVO implantable lens for nearsightedness.

Why STAAR Surgical Stock Is Surging Today

Tesla

Investors hope for another solid week for the Nasdaq Composite.

Tesla Plans Another Stock Split, but This Tiny Nasdaq Stock Jumped Even More

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the EVO/EVO+ Visian® Implantable Collamer® Lens (“EVO”) for the correction of myopia and myopia with astigmatism. Myopia, which is also known as nearsightedness or the need for distance vision correction, is the most com

STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses

Home Depot

Rambus

Two sample Breakout Stocks for Week 12 with better than 10% short-term upside potential and a Dow stock pick.

Week 12 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge

BTIG upgraded Implantable lenses-focused Staar Surgical Company (NASDAQ: STAA) to Buy from Neutral with a $98 price target.  Analyst Ryan Zimmerman believes that the Company's fundamentals will likely improve in 2H of 2022 as U.S. physicians appear more apt to try EVO upon.

BTIG Upgraded Staar Surgical Stock - Read Why

STAAR Surgical Company's (STAA) CEO Caren Mason on Q4 2021 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 18.75% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Q4 Earnings Top Estimates

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Overview Net Sales of $59.0 Million Up 28% from the Prior Year Quarter ICL Sales of $53.0 Million Up 33% from the Prior Year Quarter ICL Units Up 36% from the Prior Year Quarter Gross Margin a

STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results

Its high valuation is a major factor that could dissuade some investors for now.

Down Over 50% in 6 Months, Is STAAR Surgical Still a Buy?

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on Wednesday, February 23, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, February 23 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financi

STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 23, 2022

Staar Surgical (STAA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Staar Surgical (STAA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Staar Surgical (STAA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Staar Surgical (STAA) Loses 14.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary results for the fourth quarter and fiscal year ended December 31, 2021. The Company expects total net sales for the fourth quarter to be approximately $59 million and full year net sales to be approximately $230 million. GAAP earnings per share is expected to be approximately $0.10

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results

STAAR Surgical Company (STAA) CEO Caren Mason on Q3 2021 Results - Earnings Call Transcript

News for STAAR Surgical Stock (STAA)